We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Rheumatology

Journal Scan / Research · October 31, 2022

Risk of MACE With Tofacitinib vs TNF Inhibitors in Patients With Rheumatoid Arthritis With or Without a History of Atherosclerotic Cardiovascular Disease

Annals of the Rheumatic Diseases


Additional Info

Annals of the Rheumatic Diseases
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Ann. Rheum. Dis 2022 Sep 22;[EPub Ahead of Print], C Charles-Schoeman, MH Buch, M Dougados, DL Bhatt, JT Giles, SR Ytterberg, GG Koch, I Vranic, J Wu, C Wang, K Kwok, S Menon, JL Rivas, A Yndestad, CA Connell, Z Szekanecz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading